EMEA-001395-PIP01-12

  • Email
  • Help

Overview

Product details for -
Invented name-
Active substance

Quilizumab

Decision numberP/0271/2013
PIP numberEMEA-001395-PIP01-12
Pharmaceutical form(s)Solution for injection
Condition(s)/indication(s)

Treatment of asthma

Route(s) of administrationSubcutaneous use
PIP applicant

Roche Registration Limited
United Kingdom
Tel. +41 6168 79411
E-mail: info.paediatrics@roche.com

Decision typeP: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

Related documents